CareDx’s AlloSeq cfDNA Awarded CE Mark Approval
AlloSeq cfDNA is an innovative kit based solution, run on next generation sequencing (NGS) platforms, that enables measurement of dd-cfDNA in labs outside of the US.
“AlloSeq cfDNA provides a measure of organ injury that can help monitor transplant patient outcomes. With the CE mark, we can begin our pan-European dd-cfDNA registry and studies with CareDx,” said Dr.
“Implementing AlloSeq cfDNA in my laboratory was easy, and with minimum training my staff was able to precisely measuring donor-derived cfDNA in our transplant recipient samples,” said
“Transplantation is global, and
For more information, please visit: www.CareDx.com
Chief Marketing Officer,
Source: CareDx, Inc.